Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotechnology symbols : Bmy save search
Envisagenics Announces Research Collaboration with Bristol Myers Squibb
Published: 2022-11-29 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.42%
H: 0.38%
C: 0.28%
research collaboration
Intensity Therapeutics' INT230-6 Data will be presented at the 2022 Society for Immunotherapy of Cancer Meeting
Published: 2022-11-11 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -1.61%
H: 0.45%
C: -2.74%
int230 immunotherapy meeting cancer
BioSpace Movers & Shakers, April 1
Published: 2022-04-01 (Crawled : 15:00) - biospace.com/
RCOR | $3.2 0.0%
|
|
| O: 0.0%
H: 3.19%
C: -4.01%
WMT | News | $59.87 1.32% -0.23% 19M
|
Retail Trade
|
| O: 0.5%
H: 1.08%
C: 0.9%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.64%
H: 0.6%
C: 0.57%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.22%
H: 1.01%
C: 0.86%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.41%
H: 0.11%
C: -0.22%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -0.48%
H: 4.07%
C: 1.39%
NKTX | $7.16 -5.29% -5.59% 680K
|
Health Technology
|
| O: -1.23%
H: 4.98%
C: 1.78%
ALEC | $5.27 -1.31% -1.33% 380K
|
Health Technology
|
| O: -0.21%
H: 2.39%
C: -1.05%
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
int230 symposium therapeutics therapy results cancer breast cancer metastatic breast cancer
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
Published: 2021-09-16 (Crawled : 09:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.41%
H: 1.11%
C: 0.76%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.23%
H: 0.31%
C: -1.02%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.0%
H: 0.83%
C: 0.34%
renal cell carcinoma
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.